Pain is a debilitating condition that affects the life of one in five Australians and has significant socioeconomic impact. Currently available pain killers often do not work, or have intolerable side effects including sedation and addiction. We have discovered a novel compound that avoids these side effects and provides effective analgesia as well as opioid-sparing effects in a number of relevant animal models. The aim of this project is to progress the compound towards clinical development.
Preclinical Development Of Complement C5aR Antagonists For The Treatment Of Motor Neuron Disease
Funder
National Health and Medical Research Council
Funding Amount
$593,326.00
Summary
There is no cure for Motor Neuron Disease (MND) resulting in 2 Australian’s dying each day. Modification of the inflammation is one potential means of slowing MND. Our research team has identified a new series of potent anti-inflammatory compounds that may have potential to treat this disease. Our project will test these compounds in animal models of MND, and validate their usefulness in human MND samples. Ultimately, this work may contribute to the discovery of a new treatment for MND.